Myriad Genetics' Q2 Revenues Climb 8 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fiscal second-quarter revenues for Myriad Genetics rose 8 percent, driven by sales of its BRACAnalysis product, the company reported after the close of the market on Thursday.

For the three months ended Dec. 31, 2010, revenues for the molecular diagnostics firm rose to $100.4 million, compared to $92.8 million a year ago, surpassing consensus Wall Street estimates of $98.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.